The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory
(r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients …

Background CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a
promising treatment modality for an increasing number of B-cell malignancies. However …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma …

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the
treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant …

Summary CD19 CAR‐T have emerged as a new standard treatment for relapsed/refractory
(r/r) large B‐cell lymphoma (LBCL). CAR‐T real‐world (RW) outcomes published to date …

Anti-CD19 chimeric antigen receptor T (CAR-T) cells have demonstrated activity against
relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and immune effector cell …

COI notes: Conflicts of Interest: GI declares having received honoraria from BMS/Celgene,
Gilead, Novartis, Janssen and Roche. KR declares having received research funding and …

Chimeric antigen receptor-modified (CAR) T-cell therapy targeting CD19 has revolutionized
the treatment of relapsed or refractory B-cell lymphomas. Based on unprecedented …